DDInter717 DDInter899
Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients typically display delayed development and neurocognitive impairment.[A214694, A214709, A214712, A214715] Fenfluramine is a serotonergic phenethylamine originally used as an appetite suppressant until concerns regarding cardiotoxicity in obese patients lead to its withdrawal from the market in 1997.[A214694, A214718, A11906] Through its ability to modulate neurotransmission, fenfluramine has reemerged as an effective therapy against pharmacoresistant seizures, such as those involved in Dravet syndrome.[A214688, A214691, A214700] Fenfluramine was granted initial FDA approval in 1973 prior to its withdrawal
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Fenfluramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolterodine
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Fenfluramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eptifibatide
Fenfluramine {u} may lead to a major life threatening interaction when taken with {v} Phendimetrazine
Fenfluramine {u} may lead to a major life threatening interaction when taken with {v} Fluvoxamine
Fenfluramine may cause a minor interaction that can limit clinical effects when taken with Tolterodine
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Fenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Eptifibatide
Fenfluramine may lead to a major life threatening interaction when taken with Phendimetrazine
Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine